This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
"We saw reduced overall blood pressure in patients who received the high dose of pterostilbene," said the study's principal investigator,
Daniel M. Riche, PharmD, Cardiometabolic Clinic Coordinator at the
University of Mississippi School of Pharmacy. "The results of this study highlight that pterostilbene is a promising ingredient in the area of cardiometabolics."
Pterostilbene is believed by many experts to show great promise for supporting heart health,,,,, cognitive function,,
anti-aging,, weight loss and other metabolic disorders. Pterostilbene has superior biological activity,,,,, better oral bioavailability,, and metabolizes more slowly in the body than other antioxidant polyphenols (substances from plants that tend to prevent or neutralize the damaging effects of free radicals), resulting in more prolonged antioxidant activity.,,,
The study, a
double-blind, placebo-controlled trial, included 80 adults averaging 54 years of age with high cholesterol (total cholesterol of 200 or greater and/or LDL cholesterol of 100 or greater). Most participants were women (71%) and some had been diagnosed with high blood pressure (55%). The mean average baseline systolic blood pressure (BP) was 127.4 mmHg and the mean average baseline diastolic BP was 79.3 mmHg. The
American Heart Association guidelines state that >119 mmHg systolic BP and >79 mmHg diastolic BP are classified as pre-hypertensive. Twice daily, participants received high (125 mg) doses of pterostilbene, low (50 mg) doses of pterostilbene, pterostilbene (50 mg) with grape extract (100 mg), or placebo. The investigators assessed participants' blood pressure, body weight and blood lipids at the beginning and end of the study.
By the end of the study, participants in the high-dose pterostilbene group (250 mg/day) achieved significant reductions in BP compared to placebo: 7.8 mmHg in systolic BP (p < 0.01) and 7.3 mmHg in diastolic BP (p < 0.001), without serious adverse events. The only change in lipids was an increase in LDL cholesterol with pTeroPure (24.9 mg/dL, p < 0.001), which was less among participants on cholesterol-lowering medication and was not seen among those who also received the grape extract. Participants not on cholesterol medication also achieved a minor average reduction in body weight (reduced body mass index 0.59 kg/m
2) with pTeroPure. ChromaDex plans to conduct further studies specific for weight reduction to evaluate this trend.
"With high blood pressure affecting more than 76 million adults in the U.S., we are thrilled that these findings show pTeroPure to be effective at reducing blood pressure," said
Frank Jaksch Jr., CEO and co-founder of ChromaDex. "With limited non-prescription options to address this 'silent killer,' these results will allow pTeroPure to carry a claim of being 'clinically proven,' an attribute that should have a meaningful impact on demand for the ingredient."
pTeroPure is the key novel ingredient in
BluScience™, ChromaDex's recently launched line of dietary supplements. BluScience is now available in more than 17,000 outlets in the U.S., including national drugstore chains, wholesalers and mass channel and internet distributors.
About ChromaDex ®:
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products include patented pTeroPure
® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40% cyanidin-3-glucoside and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. For more information about pTeroPure, visit
www.pteropure.com or call 949-600-9694.
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.